ACR 2022 Tweet by Md Yuzaiful Md Yusof

#ACR22 Abstr#0783. Rituximab impacts on humoral immunity. Our study on 400 RMD pts showed:

Breakthrough infection 30% mostly mild; Severe 4%; 1 death

Poor outcomes predicted by comorbidities & low IgG

Risk reduced by 50% with each vac dose

OK for RTX if vaccinated @RheumNow